Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Multi-Center Study to Evaluate the Lipid Regulating Effects of 1-Methylnicotinamide (1-MNA)
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs N-1-methylnicotinamide (Primary)
- Indications Hyperlipoproteinaemia type V; Hypertriglyceridaemia
- Focus Therapeutic Use
- 13 Jan 2009 Actual end date (Nov 2008) added as reported by ClinicalTrials.gov.
- 13 Jan 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.